Idursulfase clinical trials
Also written Elaprase.
How each study uses idursulfase is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 24 Jul 2006 · ELAPRASE · BLA 125151 (FDA, Drugs@FDA)
- European Union
- 8 Jan 2007 · Elaprase · EMEA/H/C/000700 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2007 | 1 |
| 2010 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 0
Shire (6) · Takeda (4) · Denali Therapeutics Inc. (1) · Green Cross Corporation (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Idursulfase is the comparator. A study of two new drugs counts under both.
- 1Pabinafusp alfa · JCR Pharmaceuticals Co., Ltd. · next primary completion Oct 2027
Studies
Open first, then newest update. How each study uses idursulfase is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)Active, not recruitingPhase 2/3Denali Therapeutics Inc.NCT05371613Written as idursulfaseHow we know
- Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of AgeCompletedPhase 4ShireNCT02455622Written as Elaprase for intravenous (IV) infusionHow we know
- A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)WithdrawnPhase 4TakedaNCT05494593Written as ELAPRASEHow we know
- Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive ImpairmentActive, not recruitingPhase 2/3TakedaNCT06031259Written as Idursulfase-ITHow we know
- An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive ImpairmentCompletedPhase 1/2TakedaNCT01506141Written as Idursulfase-ITHow we know
- Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094CompletedPhase 2/3ShireNCT02412787Written as Idursulfase-ITHow we know
- A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in IndiaCompletedPhase 4TakedaNCT05058391Written as ElapraseHow we know
- A Study of GC1111 in Hunter Syndrom PatientsCompletedPhase 3Green Cross CorporationNCT03920540Written as GC1111How we know
- Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive ImpairmentCompletedPhase 2/3ShireNCT02055118Written as idursulfase-ITHow we know
- Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)CompletedPhase 2/3ShireNCT00069641Written as Iduronate-2-sulfatase enzyme replacement therapyHow we know
- Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving IdursulfaseCompletedPhase 2/3ShireNCT00630747Written as IdursulfaseHow we know
- Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase TherapyCompletedPhase 4ShireNCT00607386Written as IdursulfaseHow we know
As the comparator · 2 — what is tested is compared with idursulfase
- A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)Active, not recruitingPhase 3JCR Pharmaceuticals Co., Ltd.NCT04573023Written as IdursulfaseHow we know
- Study of Idursulfase-beta (GC1111) in Hunter SyndromeStatus unknownPhase 2Green Cross CorporationNCT02663024Written as idursulfaseHow we know
Codes
What other systems call idursulfase · ClinicalTrials.gg INT005050
- MeSH (NLM) C517982idursulfaseOne source ClinicalTrials.gov
- UNII (FDA) 5W8JGG2651IDURSULFASEConfirmed FDA, Wikidata
- RxNorm 644101Confirmed FDA, Wikidata
- Wikidata Q415801idursulfaseConfirmed FDA, Wikidata
- NCI Thesaurus C65883IdursulfaseOne source FDA
- DrugBank DB01271One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C517982 | idursulfase | One source ClinicalTrials.gov |
| UNII (FDA) | 5W8JGG2651 | IDURSULFASE | Confirmed FDA, Wikidata |
| RxNorm | 644101 | — | Confirmed FDA, Wikidata |
| Wikidata | Q415801 | idursulfase | Confirmed FDA, Wikidata |
| NCI Thesaurus | C65883 | Idursulfase | One source FDA |
| DrugBank | DB01271 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.